AIHealthcare Analytics

AI Device Firm Payments to Physicians — Conflicts of Interest and Transparency

Penn LDI (Leonard Davis Institute of Health Economics) research examines AI device firm payments to physicians, identifying potential conflicts of interest in the clinical adoption of AI medical devices. As AI device companies seek to drive adoption through physician champions and key opinion leaders, financial relationships between companies and physicians may influence prescribing, referral, and adoption decisions in ways that are not always transparent to patients or institutions.

Scope of the Issue. The Penn LDI analysis maps the financial relationships between AI medical device companies and physicians, applying the transparency frameworks developed for pharmaceutical industry payments (under the Sunshine Act) to the AI device context. The research identifies that AI device payments to physicians are less systematically tracked and disclosed than pharmaceutical payments, creating a transparency gap.

Implications for Clinical Adoption. Physician payments from AI device firms may take various forms: consulting fees, advisory board compensation, research funding, or speaking honoraria. When physicians who receive such payments are also making procurement recommendations or serving as clinical champions for AI tools, the potential for conflicts of interest is significant. Greater disclosure requirements—analogous to those applied to drug company payments—may be warranted as AI medical device adoption accelerates.